Amgen stock edges higher as Q3 2026 results report date announcement

Traders Union
All News
Business & Wealth
Companies
Amgen stock edges higher to $451.54

Highlights

Amgen will announce its third quarter 2026 earnings on November 3, with a conference call scheduled for 4:30 p.m.
Shares of Amgen edge higher to $451.54, giving the company a market value near $224.29 billion on trailing revenue of $38.09 billion.
52 of 136 analysts rate Amgen a buy, 17 recommend selling, and the median price target is $405.

Amgen announced on October 17, 2026 that it will report its third quarter 2026 financial results on Tuesday, November 3. According to PR Newswire, the company will hold a conference call with the investment community at 4:30 p.m. following the release.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish structure holds as price approaches overbought conditions

Price is sitting right at support from the prior weekly high at $450.89. The daily chart remains bullish with shares holding above their MA-20, MA-50, and MA-200. RSI at 64.4 shows the advance is approaching overbought territory, which may begin to limit further upside in the near term. The move higher so far aligns with the broader bullish structure that has emerged over the past week.

Upside favored as probabilities support buyers on breakout watch

To confirm whether the recent event is being reflected in the price, traders should watch for a close above the recent range to indicate buyers are taking control. The session started with a gap up from $447.95 to $452.43, but price has since given back part of those early gains. Even so, the probabilities over the next five trading days favor the upside at more than 80%, with less than 20% chance of a move lower, and an expected trading range of $446.25 to $456.82. A drop below $450.89 would show the move is being faded, while a strong close above the recent range would confirm buyers' commitment. On the weekly chart, the longer-term picture stays firmly constructive.

Earlier, analysts noted that Amgen's technical outlook was buoyed by advances in its clinical portfolio, particularly following approval and positive data for its DLL3-targeting therapy. With shares hovering above prior resistance and the upcoming earnings report acting as a catalyst, further confirmation of bullish momentum could hinge on a decisive close above the current trading range.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.